 | ||
Setrobuvir (INN, USAN, also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C. It was discovered at Anadys Pharmaceuticals. In 2011, Roche acquired Anadys in order to develop setrobuvir. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.
Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase.
Its development was discontinued on July 15, 2015.
References
Setrobuvir Wikipedia(Text) CC BY-SA